Do adjuvant aromatase inhibitors increase the cardiovascular risk in postmenopausal women with early breast cancer? Meta-analysis of randomized trials.

F, Cuppone; E, Bria; S, Verma; KI, Pritchard; S, Gandhi; P, Carlini; M, Milella; C, Nisticò; E, Terzoli; F, Cognetti; D, Giannarelli

doi:10.1002/cncr.23171

Public

Do adjuvant aromatase inhibitors increase the cardiovascular risk in postmenopausal women with early breast cancer? Meta-analysis of randomized trials.

Shared by NobleBlocks on Jan 1, 2008 • 12:00 AM UTC

Authors:

Cuppone F

Bria E

Verma S

Abstract

<h4>Background</h4>Despite the advantages from using aromatase inhibitors (AIs) compared with tamoxifen for early breast cancer, an unexpectedly greater number of grade 3 and 4 cardiovascular events (CVAE) (as defined by National Cancer Institute of Canada-Common Toxicity Criteria [version 2.0] was ...

Discussions